RCC adjuvant pembroluzimab benefit estimation for 5y OS - Evidencio
RCC adjuvant pembroluzimab benefit estimation for 5y OS

This tool estimates the 5-year survival benefit of 1-year adjuvant anti-PD1 treatment after surgical R0 resection for clear-cell renal cell carcinoma (ccRCC). The calculation uses the average death-rate per year of any cause in The Netherlands (CBS), the cancer-specific survival based on the Leibovich score (2018 version) and the hazard ratio (HR) for adjuvant anti-PD1 therapy based on the KN-564 study.

Sex is only relevant for the death-of-any-cause estimation, not for adjustment of the KN-564 HR. The HR can be adjusted for WHO ECOG performance, based on the KN-564 findings: without ECOG input the model uses 0.62, for ECOG-1 0.82 and for ECOG-0 0.55. The 10y survival prediction is for consultation without adjuvant therapy only, as current HR can not be extrapolated that far in the future.

Autores de la investigación: Ninguno
Versión: 2.0
  • Público
  • Oncología
  • {{ modelType }}
  • Detalles
  • Validar algoritme
  • Guardar entrada
  • Entrada de carga
Mostrar
Unidades

{{section.title}}

Calcular el resultado

Establezca más parámetros para realizar el cálculo

Out of a 100 treated patients, Patients will survive anyhow for 5 years or more

{{ resultSubheader }}
{{ chart.title }}
Intervalo de resultados {{ additionalResult.min }} a {{ additionalResult.max }}

Información condicional

Please don't forget to counsel your patient for participation in the PRO-RCC national cohort!

{{ file.classification }}
PRO
Nota
Las notas sólo son visibles en la descarga de resultados y no serán guardadas por Evidencio

Este algoritme se proporciona con fines educativos, formativos e informativos. No debe utilizarse para apoyar la toma de decisiones médicas ni para prestar servicios médicos o de diagnóstico. Lea nuestro disclaimer.

Algoritmer subyacentes Parte de
Comentarios
Comentario
Escriba un comentario
Los comentarios son visibles para cualquiera

Comentarios sobre el algoritme

Aún no hay comentarios 1 comentario {{ model.comments.length }} Comentarios
En {{ comment.created_at }} {{ comment.user.username }} un autor ya no registrado escribió:
{{ comment.content }}
logo

Inicia sesión para activar las funciones de impresión de Evidencio

Para poder utilizar las funciones de impresión de Evidencio, debe estar conectado.
Si no tiene una cuenta de la Comunidad Evidencio puede crear su cuenta personal gratuita en:

https://www.evidencio.com/registration

Resultados impresos - Ejemplos {{ new Date().toLocaleString() }}


Beneficios de la Cuenta Comunitaria Evidencio


With an Evidencio Community account you can:

  • Create and publish your own prediction algorithms.
  • Share your prediction algorithms with your colleagues, research group, organization or the world.
  • Review and provide feedback on algorithms that have been shared with you.
  • Validate your algorithms and validate algorithms from other users.
  • Find algorithms based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction algorithms and their data.
  • Use patient specific protocols and guidelines based on sequential algorithms and decision trees.
  • Stay up-to-date with new algorithms in your field as they are published.
  • Create your own lists of favorite algorithms and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.


Descargo de responsabilidad: Los cálculos por sí solos nunca deben dictar la atención al paciente, y no sustituyen al juicio profesional.
Evidencio v3.35 © 2015 - 2025 Evidencio. Todos los derechos reservados